RxDoctor Payments Data

Lindsey Lassiter

Family · Jackson, MSNPI 1225325632

Payments from drug & device makers

$9,558in general payments, 2019–2025

Across 510 payments — averaging $18.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • AstraZeneca$1K
  • Mallinckrodt Hospital Products Inc.$807
  • Actelion Pharmaceuticals US, Inc.$775
  • Sanofi$573
  • Boehringer Ingelheim$522
  • plus $4K from 28 others

What the payments were for

  • Food & beverage$9,37898%
  • Education$1802%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,558 in reported general payments places this provider in the 95th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$60,233
Medicare patients
298
Services billed
1,375

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter66$43,985
Ambrisentan11$31,158
Breztri AerosphereBudesonide/Glycopyr/Formoterol27$22,803
EliquisApixaban14$12,426
SymbicortBudesonide/Formoterol Fumarate31$7,819
Incruse ElliptaUmeclidinium Bromide22$7,580
BreynaBudesonide/Formoterol Fumarate19$3,593
Albuterol Sulfate HfaAlbuterol Sulfate76$2,928
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$1,606
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav53$710
Montelukast Sodium23$121
Prednisone31$99
Azithromycin17$98
Fluconazole12$72
Levofloxacin18$50

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Incruse Ellipta$1,865$51,56588 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,468$30,62258 claims
PfizerEliquis$158$12,42614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,007 family providers in Mississippi.

Other family in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →